LOGIN  |  REGISTER
Chimerix

List of Biotech and Pharma Companies Using Artificial Intelligence

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 725.72
-31.88 -4.21
5.36M
899.32M
US$ 652.650B
US$ 97.92
-2.78 -2.76
14.89M
2.53B
US$ 247.740B
US$ 36.42
-0.27 -0.74
160,263
5.52B
US$ 201.040B
US$ 383.42
1.63 0.43
1.67M
381.22M
US$ 146.170B
US$ 88.08
0.92 1.06
8.75M
1.28B
US$ 112.740B
US$ 237.38
1.08 0.46
1.95M
290.01M
US$ 68.840B
US$ 84.74
-0.26 -0.31
2.66M
456.87M
US$ 38.720B
US$ 197.36
-0.30 -0.15
1.11M
181.50M
US$ 35.820B
US$ 216.59
1.84 0.86
697,033
162.35M
US$ 35.160B
US$ 419.26
-9.36 -2.18
782,423
81.88M
US$ 34.330B
US$ 84.38
-0.46 -0.54
5.03M
390.60M
US$ 32.960B
US$ 111.93
-0.83 -0.74
447,197
239.74M
US$ 26.830B
US$ 109.56
0.62 0.57
1.03M
199.07M
US$ 21.810B
US$ 136.67
-0.70 -0.51
1.09M
158.60M
US$ 21.680B
US$ 151.20
-0.46 -0.30
732,257
111.62M
US$ 16.880B
US$ 69.73
-0.24 -0.34
6.09M
226.94M
US$ 15.820B
US$ 118.39
-1.14 -0.95
637,224
121.70M
US$ 14.410B
US$ 34.06
0.30 0.89
10.55M
384.82M
US$ 13.110B
US$ 75.83
-0.27 -0.35
949,477
158.89M
US$ 12.050B
US$ 25.29
0.24 0.96
2.04M
435.99M
US$ 11.030B
US$ 46.00
0.10 0.22
1.17M
222.26M
US$ 10.220B
US$ 102.42
2.33 2.33
900,700
86.66M
US$ 8.880B
US$ 163.50
-2.30 -1.39
988,139
51.14M
US$ 8.360B
US$ 37.47
0.11 0.29
904,042
172.09M
US$ 6.450B
US$ 35.15
0.40 1.15
2.42M
152.40M
US$ 5.360B
US$ 29.16
-0.16 -0.55
1.22M
170.18M
US$ 4.960B
US$ 59.86
-1.02 -1.68
808,897
74.03M
US$ 4.430B
US$ 16.02
-0.61 -3.67
2.97M
236.39M
US$ 3.790B
US$ 11.66
-0.10 -0.85
856,039
160.99M
US$ 1.880B
US$ 46.52
-0.40 -0.85
345,127
38.23M
US$ 1.780B
US$ 4.08
0.01 0.25
5.41M
412.08M
US$ 1.680B
C$ 6.53
-0.01 -0.15
961,949
248.96M
C$ 1.630B
US$ 17.69
-0.12 -0.67
455,732
89.70M
US$ 1.590B
US$ 9.19
0.03 0.33
2.94M
172.17M
US$ 1.580B
US$ 10.00
-0.16 -1.57
2.51M
115.03M
US$ 1.150B
US$ 14.58
0.04 0.28
312,669
77.11M
US$ 1.120B
US$ 3.67
-0.21 -5.41
1.96M
186.64M
US$ 684.970M
US$ 4.84
0.00 0.00
0
130.82M
US$ 633.170M
US$ 3.02
-0.02 -0.66
749,336
168.92M
US$ 510.140M
US$ 8.41
0.07 0.84
3.14M
58.52M
US$ 492.150M
US$ 10.83
0.63 6.18
1.19M
45.20M
US$ 489.520M
US$ 3.06
0.05 1.66
1.59M
138.95M
US$ 425.190M
US$ 17.41
0.16 0.93
52,272
23.48M
US$ 408.790M
US$ 5.49
-0.01 -0.18
1.75M
60.85M
US$ 334.070M
US$ 2.90
0.13 4.69
2.49M
114.86M
US$ 333.090M
C$ 1.85
0.08 4.52
637,690
165.88M
C$ 306.880M
US$ 3.06
0.08 2.68
49,012
66.44M
US$ 203.310M
US$ 2.93
-0.19 -6.09
279,427
64.80M
US$ 189.860M
US$ 4.57
0.07 1.56
384,986
37.47M
US$ 171.240M
US$ 5.30
0.00 0.00
0
27.08M
US$ 143.520M
C$ 0.14
0.03 28.57
332,900
100.02M
C$ 13.500M
US$ 2.35
0.00 0.00
0
49.43M
US$ 116.160M
US$ 0.71
-0.04 -5.73
625,368
158.72M
US$ 112.220M
US$ 0.83
-0.02 -2.43
1.06M
125.80M
US$ 103.910M
US$ 2.61
-0.16 -5.78
568,581
37.42M
US$ 97.670M
US$ 4.81
-0.06 -1.23
115,464
18.42M
US$ 88.510M
US$ 2.17
-0.03 -1.36
51,774
37.10M
US$ 80.510M
C$ 0.94
0.09 10.59
118,800
74.08M
C$ 69.640M
US$ 2.03
-0.06 -3.01
394
31.02M
US$ 62.880M
US$ 2.14
0.00 0.00
81,194
26.67M
US$ 57.070M
US$ 0.98
0.0076 0.78
71,354
57.89M
US$ 56.670M
US$ 1.97
0.07 3.42
708,626
26.35M
US$ 51.780M
US$ 0.24
0.003 1.28
37.92M
186.89M
US$ 44.480M
C$ 0.47
0.02 3.33
4,500
93.38M
C$ 43.420M
US$ 1.96
-0.12 -5.77
615,769
20.75M
US$ 40.670M
US$ 3.69
0.09 2.50
91,528
10.78M
US$ 39.780M
US$ 5.63
2.52 81.03
9,302
6.63M
US$ 37.330M
C$ 0.33
-0.005 -1.52
11,000
113.10M
C$ 36.760M
US$ 0.21
-0.01 -4.81
893,595
162.86M
US$ 33.550M
US$ 1.17
0.08 7.34
100,710
27.99M
US$ 32.750M
US$ 2.81
-0.04 -1.23
121,691
9.15M
US$ 25.670M
US$ 0.53
-0.04 -6.85
389,016
40.44M
US$ 21.430M
US$ 0.19
-0.01 -5.60
6.96M
101.99M
US$ 19.790M
US$ 0.85
0.02 1.80
494,639
23.26M
US$ 19.770M
US$ 9.27
-0.29 -3.03
44,344
2.06M
US$ 19.100M
US$ 2.12
0.01 0.47
90,653
8.71M
US$ 18.470M
C$ 0.20
0.00 0.00
2,500
90.89M
C$ 18.180M
US$ 3.09
-0.27 -8.04
58,670
5.87M
US$ 18.140M
C$ 0.19
-0.02 -9.52
138,631
90.29M
C$ 17.160M
US$ 0.53
-0.03 -5.36
669,454
31.06M
US$ 16.460M
C$ 0.10
0.00 0.00
65,500
159.67M
C$ 15.970M
C$ 0.04
-0.005 -12.50
243,000
451.63M
C$ 15.810M
US$ 0.60
-0.005 -0.83
254,546
23.87M
US$ 14.200M
US$ 0.03
-0.007 -20.00
103,796
407.29M
US$ 11.400M
US$ 4.69
0.04 0.86
42,258
2.22M
US$ 10.410M
US$ 1.50
-0.08 -5.06
868,263
6.90M
US$ 10.350M
C$ 0.18
0.03 16.67
64,500
55.51M
C$ 9.710M
US$ 0.63
-0.02 -3.69
230,872
14.09M
US$ 8.820M
US$ 0.35
-0.06 -15.30
8,542
24.39M
US$ 8.560M
US$ 0.07
-0.0028 -3.79
13.01M
119.86M
US$ 8.510M
US$ 1.21
-0.13 -9.70
329,151
6.67M
US$ 8.070M
C$ 0.06
0.00 0.00
0
133.13M
C$ 7.990M
US$ 1.75
0.01 0.57
21,809
4.22M
US$ 7.380M
US$ 0.32
0.0051 1.60
523,616
22.41M
US$ 7.240M
C$ 0.12
-0.02 -14.29
387,495
59.81M
C$ 7.180M
US$ 0.59
-0.13 -17.92
1.38M
10.83M
US$ 6.400M
US$ 0.96
0.11 12.69
108,342
5.67M
US$ 5.430M
C$ 0.05
0.00 0.00
38,500
76.84M
C$ 3.460M

Latest News From Biotech and Pharma Companies Using Artificial Intelligence


Sutter Health and GE HealthCare enter strategic partnership to benefit patients, physicians and clinicians with advanced, AI-powered imaging

The multi-year collaboration enables expanded access to quality diagnostic care for patients in California and provides Sutter physicians and clinicians with access to technology advances and innovations. It will also drive ongoing, comprehensive training and education, fostering future healthcare professionals representing the diverse communities they serve. Sutter Health, one of the top integrated health delivery systems in the country with more than 300 facilities,... Read more


Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care

CHICAGO / Jan 14, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision... Read more


Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell Ainos is now inviting robotics and humanoid companies worldwide to join its Ainos Alliance, leveraging nearly a decade of research, development, and success in this field. With multiple patents secured, AI Nose represents the culmination of years of innovation and is poised to lead the next wave of advancements in robotics. This is the perfect time to collaborate and integrate this... Read more


IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions

RESEARCH TRIANGLE PARK, N.C. / Jan 13, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences. The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered solutions. This collaboration between IQVIA... Read more


Illumina and NVIDIA collaborate to decode biology and propel precision health

Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development,... Read more


Waystar unveils transformative generative AI innovation to help providers recover billions of dollars tied to 450 million annual denied claims

Healthcare providers gain access to first-of-its-kind generative AI technology, leading to faster and more accurate payments LEHI, Utah, and LOUISVILLE, Ky., Jan. 13, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today announced the launch of Waystar AltitudeAI™, a comprehensive set of AI capabilities for providers, including AltitudeCreate™, a new generative AI innovation focused on appealing denied claims. By... Read more


Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI

VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the successful achievement of a shortlist of AI-generated molecules targeting ATR (Ataxia Telangiectasia and Rad3-related protein) with specific designs for central nervous system (CNS) penetration. This milestone represents... Read more


Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine

MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using advanced Artificial Intelligence (AI) based design platforms and protein evolutionary workflows. This expanded portfolio from Bio-Techne's R&D Systems brand includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available both for research use only (RUO)... Read more


Kovo+ Expands AI-Powered Automation with Strategic Agreement with Connective Health Strategies

Vancouver, British Columbia--(Newsfile Corp. - January 9, 2025) - Kovo+ Holdings Inc. (TSXV: KOVO) (formerly Kovo HealthTech Corporation) ("Kovo" or the "Company") is pleased to announce that it has entered into a strategic software as a service license agreement (the "Agreement") with Connective Health Strategies, LLC ("Connective"), expanding the Company's suite of automation tools with AI-powered capabilities. "We are incredibly excited to expand Kovo's suite of automation... Read more


Tempus AI Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict... Read more


Movano Health Launches EvieAI Virtual Wellness Assistant

Newest Evie Ring feature is the first medical journal trained AI companion in a wearable PLEASANTON, Calif., Jan. 8, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced the latest enhancement to its Evie smart ring for women with the beta release of EvieAI, the first wearable-based virtual wellness assistant trained exclusively with data from medical journals. The new feature enables Evie users to answer health questions quickly, reliably and... Read more


Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. AMD will also make a $20 million investment in Absci, structured as a private investment in public equity (PIPE), underscoring... Read more


Clover Health: Counterpart Health Deploys Counterpart Assistant with Leading Accountable Care Organization

WILLMINGTON, Del., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced it has successfully deployed its Counterpart Assistant technology within Duke Connected Care (DCC), a recognized leader in accountable care and part of the prestigious Duke University Health System. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover Health”). Based in Durham,... Read more


NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications  NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that it is expanding... Read more


Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation

VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, announces the successful synthesis of novel small-molecule drug candidates designed under the Company’s artificial intelligence (AI) platform collaboration. The initial batch of compounds have arrived at Rakovina’s state-of-the-art wet-lab... Read more


Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul Combines Predictive Oncology’s AI-driven multi-omic drug discovery platform with Renovaro’s AI Cube multi-omic artificial intelligence to advance both cancer... Read more


Oncotelic Therapeutics Implements PDAOAI Platform

AGOURA HILLS, Calif., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), today announced the implementation of its artificial intelligence (AI) platform PDAOAI. The platform is designed to streamline document search and analysis, to address the growing needs of knowledge-based industries including pharmaceutical and biotechnology. We have been enhancing the capabilities of the platform over the past... Read more


Dexcom Launches the First Generative AI Platform in Glucose Biosensing

Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform Dexcom GenAI-enabled technology will leverage Google Cloud’s Vertex AI platform and Gemini models and will initially enhance Stelo’s Weekly Insights feature by providing users with more personalized content based on glucose levels, activity and sleep Proprietary platform lays foundation for future GenAI advancements across the Dexcom product portfolio... Read more


Forian Partners With Databricks to Expand Access to Advanced Healthcare Analytics

NEWTOWN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced a partnership with Databricks, the data and AI company, to deliver access to its Chartis™ product, which maps physician and organization affiliations, through Databricks Marketplace. This collaboration will empower healthcare organizations... Read more


Qiagen Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

Ingenuity Pathway Analysis Interpret extends analysis capabilities of human-curated knowledge base with AI technology AI-extension highlights key biological elements at work and provides summarized results and interpretations in a sharable web document, speeding up interpretation Ingenuity Pathway Analysis Interpret unlocks the full potential of biological data by streamlining interpretation process and delivering actionable insights for experiments REDWOOD CITY, Calif.... Read more


Evaxion establishes new AI-derived precision cancer vaccine concept

Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patients Novel preclinical data confirms the effectiveness of the precision vaccine approach by inducing strong T-cell responses and tumor growth inhibition in mice, thereby establishing preclinical Proof-of-Concept The approach could allow for a broader use of cancer vaccines, also for patients not responding to conventional... Read more


Spectral AI Highlights Unprecedented Collaboration with National Leaders in Burn Care for DeepView™ System Training and Validation Studies

DALLAS, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced that national leaders in burn care have dedicated more than an estimated 511 in-person days of physician engagement to the training and validation... Read more


Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring. This innovative approach aims to reduce human error, cut costs, and improve efficiency, positioning Conduit for success across its current and future portfolio. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Conduit... Read more


BioMark Diagnostics' Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction

BioMark Expands Its Liquid Biopsy Platform Receptor Status for Breast Cancer Vancouver, British Columbia--(Newsfile Corp. - December 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leader in liquid biopsy tests for early cancer detection, announced a significant advancement in its breast cancer diagnostic capabilities. A groundbreaking study published in the International Journal of Molecular Sciences (IJMS) Special Edition... Read more


GE HealthCare Expands Its Effortless Recon DL Portfolio, Bringing Advanced Deep Learning Image Reconstruction to Clinicians Worldwide

More than 80 percent of all health system visits include an imaging exam,i making radiology an essential part of diagnostics and healthcare and image quality a cornerstone of medicine. GE HealthCare is at the forefront of leveraging deep learning, a subset of artificial intelligence (AI), to benefit clinicians and patients with the latest technologies and solutions. CHICAGO / Dec 05, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) unveiled three new advanced deep... Read more


Ketryx Announces DeepHealth Selected Its Software to Accelerate AI-Powered Health Informatics Innovation

CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- Ketryx announced today that DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), has selected Ketryx to accelerate the delivery of AI-powered health informatics solutions. DeepHealth's solutions leverage a cloud-native operating system to drive operational efficiency, improved clinical confidence, and better care delivery. According to theFDA,... Read more


Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth WEXFORD, Pa. , Dec. 3, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce the execution of a Binding Letter of Intent... Read more


HEALWELL AI Acquires Control of Mutuo Health Solutions to Build Next Generation of AI-Powered Physician Co-Pilots

HEALWELL has acquired a majority controlling interest in Mutuo Health Solutions, a Toronto-based medical artificial intelligence company focused on developing predictive clinical AI technology. Mutuo Health's AutoScribe platform is an advanced AI-powered ambient scribe solution that transcribes clinician-patient interactions into high-quality electronic medical records in real time using natural language processing and machine learning technology. AutoScribe's speech... Read more


Spectral AI Completes Truthing of Burn Center Images, Initiates Emergency Department Image Review

DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the successful completion of truthing for all images gathered from burn centers across the United States. This milestone represents a pivotal step in training the Company's proprietary DeepView®... Read more


Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations

Leader in Women’s Health Unveils Data Underscoring Its Commitment to Reducing Bias in Breast Cancer Detection MARLBOROUGH, Mass. / Dec 02, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) yesterday presented new research demonstrating the performance of its Genius AI® Detection 2.0 software across diverse patient populations at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA). Artificial intelligence (AI) is... Read more


RadNet’s Wholly-Owned Subsidiary, DeepHealth, Launches New AI-powered Informatics and SmartTechnology™ Innovations at #RSNA2024

At RSNA 2024, DeepHealth launches new AI-powered informatics and SmartTechnology™ solutions powered by DeepHealth OS, its pioneering cloud-native operating system. These solutions, deployed on the secure, scalable, and interoperable OS, address clinical and operational challenges across the imaging value chain. DeepHealth’s AI-powered informatics portfolio features the newly introduced Diagnostic Suite™ and TechLive™1, integrated workspaces for radiologists and... Read more


GE HealthCare Highlights New Solutions Including AI-enabled Innovations to Drive Precision Care at RSNA 2024

Booth (#7330) will showcase new innovations that address the most pressing challenges in healthcare, spanning the care journey across devices, disease states and digital tools New product introductions reflect GE HealthCare’s increased R&D investment since 2022 CHICAGO / Dec 01, 2024 / Business Wire / At the Radiological Society of North America’s (RSNA) 2024 Annual Meeting taking place from Dec. 1-4 in Chicago, GE HealthCare (Nasdaq: GEHC) will exhibit more... Read more


RadNet’s Wholly-Owned Subsidiary, DeepHealth, to Use CARPL.ai's Platform to Develop a New AI Control System for Clinical AI Performance and Safety

DeepHealth and CARPL.ai have established a strategic collaboration to create a unique Artificial Intelligence (AI) control system for image interpretation to ensure AI scalability, performance monitoring, and safety, with the aim to accelerate the adoption of AI.  DeepHealth currently monitors the performance of DeepHealth’s SmartMammo™ AI-powered solution for breast cancer detection at RadNet. Through the collaboration, the two companies aim to expand, productize... Read more


iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024

NASHUA, N.H., Nov. 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5. Key highlights include the recent FDA-cleared ProFound Detection Version 4, clinical research presentations, and a new partnership... Read more


Teladoc Health Expands AI Capabilities for Hospitals and Health Systems with Advanced Virtual Sitter Solution

PURCHASE, NY, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, announced today the launch of new AI-enabled capabilities to enhance its Virtual Sitter solution to improve patient safety, address workforce challenges, and enhance care delivery for hospitals and health systems. Every year, nearly 1 million hospitalized patients experience falls, with more than 30% resulting in lasting injuries. According to the CDC, falls... Read more


Allurion Technologies Launches in the US with its First AI-Native Compounded GLP-1 Program

AllurionMeds is designed to address a critical demand from patients: The Weight Must Stay Off Features Coach Iris, a first-of-its-kind conversational AI behavioral agent for weight loss and maintenance, trained using real-world experience in over 150,000 patients Compounded GLP-1 program designed to provide long-term behavioral change while addressing weight re-gain and other negative side effects for patients Expands Allurion’s presence to all 50 states, helping to... Read more


Veeva Systems Announces AI in Vault CRM

CRM Bot and Voice Control deliver GenAI-powered assistance in Vault CRM SINGAPORE, Nov. 24, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Vault CRM Bot and Vault CRM Voice Control, two new GenAI capabilities in Vault CRM. Unveiled at Veeva Commercial Summit Europe, CRM Bot and Voice Control join a host of new innovations coming to Vault CRM next year. With these new capabilities, companies can deploy AI that will have immediate value by boosting field... Read more


Health Catalyst Launches AI-Enabled Cyber Protection Product for Healthcare

SALT LAKE CITY, Nov. 20, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of an AI-powered version of BluePrint Protect™ from Intraprise Health, LLC ("Intraprise Health"), a platform that empowers healthcare organizations to screen and identify risks related to cybersecurity threats through third parties. On... Read more



Veeva Systems Announces AI in Vault CRM

CRM Bot and Voice Control deliver GenAI-powered assistance in Vault CRM MADRID and PLEASANTON, Calif., Nov. 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Vault CRM Bot and Vault CRM Voice Control, two new GenAI capabilities in Vault CRM. Unveiled at Veeva Commercial Summit Europe, CRM Bot and Voice Control join a host of new innovations coming to Vault CRM next year. With these new capabilities, companies can deploy AI that will have... Read more


Premier Health Announces Successful AI Deployment in Quebec

MONTRÉAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian health tech company, announces that it successfully deployed AI at its two subsidiaries to meet its digital transformation, efficiency and sustainability objectives. Premier Health has deployed AI capabilities at its two Quebec per diem subsidiaries, Premier Soin and Code Bleu. The AI’s maturity has achieved a remarkable... Read more


Tarsus Pharmaceuticals Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across objective measures of Meibomian Gland Disease... Read more


$20 Billion Market Breakthrough: ImmunoPrecise Antibodies Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

Innovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for Transformative Cancer Treatments VICTORIA, British Columbia / Nov 13, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA’s cutting-edge discovery... Read more





HEALWELL AI Provides Corporate Update on Accelerating Commercialization and Expansion of Pharmaceutical Partnerships by Leveraging Its Best-in-Class Patient Identification Capabilities

HEALWELL's AI and data science subsidiaries have executed 5 new Master Services Agreements ("MSA") with new pharmaceutical partners in Q3-2024; bringing the total number of MSAs with life sciences partners to 27, which includes 6 of the top 10 pharmaceutical companies in the world. HEALWELL's AI and data science subsidiaries generated patient identification revenue from 23 of these pharmaceutical partners in Q3-2024. HEALWELL subsidiary, Khure Health, has executed an... Read more


ImmunoPrecise Antibodies Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

Rabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction VICTORIA, British Columbia / Oct 28, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was initially published in bioRxiv and subsequently... Read more


Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform

VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies announced today that it has received initial results from the proprietary Deep Docking AI platform. Rakovina employed the Deep Docking algorithm to evaluate billions of molecular structures to develop a short-list of drug candidates that have been... Read more


Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories

Enables transcription of handwritten test request forms to digitized format Utilizes innovative AI for higher accuracy and efficiency Data is securely processed with ISO27001 compliant solution WALTHAM, Mass. / Oct 22, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a digitized format. This... Read more